GlobeNewswire Inc.··Clene Inc.Clene Maps Out 2026 Regulatory Path for ALS Candidate CNM-Au8
Clene outlines 2026 regulatory milestones for ALS drug CNM-Au8, including FDA meeting, NDA submission, and Phase 3 trial, backed by $28 million funding.
CLNNFDA approvalclinical trial